Plasmid DNA is a small, circular DNA molecule that occurs in bacteria and other cellular organisms, and can replicate independently of the chromosome. Plasmid DNA is commonly used as a vector for cloning and sequencing genetic components such as DNA. It is widely used in biotechnology, pharmaceutical, gene therapy and other research sectors. Plasmid DNA is used to produce genetic vaccines, therapeutic proteins and antibodies. It is also used in gene therapy clinical trials to treat various diseases such as cancer, cardiovascular diseases, genetic diseases and others. The rising demand for innovative gene therapies and biologics coupled with increasing gene therapy clinical trials is expected to drive the global plasmid DNA manufacturing market.
The global plasmid DNA manufacturing market is estimated to be valued at US$ 901.2 Bn in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Growing demand for gene therapies to treat genetic diseases: Gene therapies are promising innovative treatments for complex diseases such as cancer, cardiovascular diseases, genetic diseases and others. The increasing success of gene therapies clinical trials is expected to boost the use of plasmid DNA, driving the market growth. According to a study published in 2019 in Gene Therapy, over 6000 clinical trials of gene and cell therapies have been or are being conducted worldwide.
Growing biotechnology and pharmaceutical industries: Growing biotechnology and pharmaceutical industries have significantly increased the demand for plasmid DNA for R&D activities, clinical trials, generic therapeutics and biologic vaccines manufacturing. The rising focus of big pharma on biologics and biosimilars is expected to contribute to the market growth over the forecast period.
High demand for plasmid DNA vectors: Plasmid DNA vectors are commonly used in process development, manufacturing and clinical development of gene therapies and biologics. The increasing demand for plasmid DNA vectors from biotech companies, gene therapy developers, CROs and CMOs for developing plasmid DNA based novel therapies is positively impacting the market growth.
The plasmids DNA manufacturing market is dominated by the research segment which holds around 60% market share. Due to increasing funding for research activities from government and private organizations more towards development of novel gene and cell therapies, the research segment is expected to witness highest growth over the forecast period. Another fast growing segment is therapeutics which holds around 25% share currently. With increasing number of ongoing clinical trials and product approvals for gene and cell therapy, the demand for plasmid DNA from therapeutics segment is projected to increase manifold.
Political: Governments across major markets are increasingly funding research activities for development of advanced therapeutics. Also, favorable regulatory guidelines related to clinical trials and product approvals are supporting the market growth.
Economic: Rising healthcare spending coupled with increasing disposable income is driving the demand for high-cost advanced therapeutics. Furthermore, high R&D investments by pharmaceutical and biotechnology companies is positively impacting the market.
Social: Growing awareness about advanced treatment options like gene and cell therapies is increasing the demand. Also, rising psychological acceptance for new therapies is another key factor.
Technological: Developments in gene synthesis and sequencing technologies have enabled larger scale, rapid and cost-effective manufacturing of plasmids DNA. Also, automation is helping in overcoming the lack of skilled labor issue.
The global plasmids DNA manufacturing market is expected to witness high growth over the forecast period. Global Plasmid DNA Manufacturing Market Size is estimated to be valued at US$ 901.2 Bn in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period 2023 to 2030.
Regional analysis related content comprises
North America leads the global market with over 40% share mainly driven by the US where majority of R&D spending and ongoing clinical trials are concentrated. Europe and Asia Pacific together account for more than 35% share. Within Asia Pacific, China and India are emerging as key markets and are expected to witness exponential growth owing to growing biopharma industry, favorable business environment and increasing adoption of advanced therapeutics.
Key players related content comprises
Key players operating in the plasmids DNA manufacturing market are Cobra Biologics and Pharmaceutical Services (Charles River Laboratories), VGXI, Inc., Aldevron (Danaher), Kaneka Corporation, Nature Technology, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult, LakePharma, Inc., MeiraGTx Limited. These players are focusing on expanding their manufacturing facilities and capacities to cater to the growing demand.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it